Silencing of the DNA Mismatch Repair Gene MLH1 Induced by Hypoxic Stress in a Pathway Dependent on the Histone Demethylase LSD1

Cell Reports

Volumn 8, Issue 2, 2014, Pages 501-513

  Lu, Yuhong ^a   Wajapeyee, Narendra ^a   Turker, MitchellS ^b   Glazer, Peter M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; COREST; HISTONE DEMETHYLASE; HISTONE H3; HISTONE H3 LYSINE 4; LSD1 PROTEIN; MAX PROTEIN; MNT PROTEIN; PLU 1 PROTEIN; PROTEIN MAD1; PROTEIN MLH1; REPRESSOR PROTEIN; UNCLASSIFIED DRUG; AZACITIDINE; COREPRESSOR PROTEIN; DECITABINE; DNA METHYLTRANSFERASE; KDM1A PROTEIN, HUMAN; MLH1 PROTEIN, HUMAN; NERVE PROTEIN; NUCLEAR PROTEIN; RCOR1 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; DNA; DNA METHYLTRANSFERASE INHIBITOR; LYSINE 4;

ARTICLE; CANCER CELL; CELL HYPOXIA; COLON CANCER; CONTROLLED STUDY; GENE SILENCING; HISTONE METHYLATION; MLH1 GENE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COLON TUMOR; GENETICS; HELA CELL LINE; HUMAN; MCF 7 CELL LINE; METABOLISM; CANCER GROWTH; DNA METHYLATION; EPIGENETICS; GENE; GENE AMPLIFICATION; GENOMIC INSTABILITY; HISTONE MODIFICATION; HUMAN CELL; HYPOXIA; MISMATCH REPAIR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AZACITIDINE; CELL HYPOXIA; CO-REPRESSOR PROTEINS; COLONIC NEOPLASMS; DNA MODIFICATION METHYLASES; GENE SILENCING; HELA CELLS; HISTONE DEMETHYLASES; HUMANS; MCF-7 CELLS; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS;

EID: 84904792660     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.06.035     Document Type: Article

References (51)

1. Aebi S., Kurdi-Haidar B., Gordon R., Cenni B., Zheng H., Fink D., Christen R.D., Boland C.R., Koi M., Fishel R., Howell S.B. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996, 56:3087-3090.
2. Baylin S.B., Ohm J.E. Epigenetic gene silencing in cancer-amechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 2006, 6:107-116.
3. Bindra R.S., Glazer P.M. Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutat. Res. 2005, 569:75-85.
4. Bindra R.S., Glazer P.M. Co-repression of mismatch repair gene expression by hypoxia in cancer cells: role of the Myc/Max network. Cancer Lett. 2007, 252:93-103.
5. Bindra R.S., Glazer P.M. Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene 2007, 26:2048-2057.
6. Bindra R.S., Schaffer P.J., Meng A., Woo J., Måseide K., Roth M.E., Lizardi P., Hedley D.W., Bristow R.G., Glazer P.M. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol. Cell. Biol. 2004, 24:8504-8518.
7. Buermeyer A.B., Deschênes S.M., Baker S.M., Liskay R.M. Mammalian DNA mismatch repair. Annu. Rev. Genet. 1999, 33:533-564.
8. Chen H., Yan Y., Davidson T.L., Shinkai Y., Costa M. Hypoxic stress induces dimethylated histone H3 lysine 9 through histone methyltransferase G9a in mammalian cells. Cancer Res. 2006, 66:9009-9016.
9. Chi P., Allis C.D., Wang G.G. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 2010, 10:457-469.
10. Ciccone D.N., Su H., Hevi S., Gay F., Lei H., Bajko J., Xu G., Li E., Chen T. KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints. Nature 2009, 461:415-418.
11. Coquelle A., Toledo F., Stern S., Bieth A., Debatisse M. A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol. Cell 1998, 2:259-265.
12. Ding J., Zhang Z.M., Xia Y., Liao G.Q., Pan Y., Liu S., Zhang Y., Yan Z.S. LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer. Br. J. Cancer 2013, 109:994-1003.
13. Drummond J.T., Anthoney A., Brown R., Modrich P. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J.Biol. Chem. 1996, 271:19645-19648.
14. Eads C.A., Danenberg K.D., Kawakami K., Saltz L.B., Blake C., Shibata D., Danenberg P.V., Laird P.W. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000, 28:E32.
15. Elsässer S.J., Allis C.D., Lewis P.W. Cancer. New epigenetic drivers of cancers. Science 2011, 331:1145-1146.
16. Esteller M., Levine R., Baylin S.B., Ellenson L.H., Herman J.G. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998, 17:2413-2417.
17. Fahrner J.A., Eguchi S., Herman J.G., Baylin S.B. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 2002, 62:7213-7218.
18. Forneris F., Binda C., Battaglioli E., Mattevi A. LSD1: oxidative chemistry for multifaceted functions in chromatin regulation. Trends Biochem. Sci. 2008, 33:181-189.
19. Francia G., Green S.K., Bocci G., Man S., Emmenegger U., Ebos J.M.L., Weinerman A., Shaked Y., Kerbel R.S. Down-regulation ofDNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents. Mol. Cancer Ther. 2005, 4:1484-1494.
20. Gore S.D., Baylin S., Sugar E., Carraway H., Miller C.B., Carducci M., Grever M., Galm O., Dauses T., Karp J.E., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006, 66:6361-6369.
21. Hayami S., Kelly J.D., Cho H.-S., Yoshimatsu M., Unoki M., Tsunoda T., Field H.I., Neal D.E., Yamaue H., Ponder B.A.J., et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 2011, 128:574-586.
22. Herman J.G., Umar A., Polyak K., Graff J.R., Ahuja N., Issa J.-P.J., Markowitz S., Willson J.K.V., Hamilton S.R., Kinzler K.W., et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA 1998, 95:6870-6875.
23. Huang Y., Greene E., Murray Stewart T., Goodwin A.C., Baylin S.B., Woster P.M., Casero R.A. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc. Natl. Acad. Sci. USA 2007, 104:8023-8028.
24. Huang Y., Stewart T.M., Wu Y., Baylin S.B., Marton L.J., Perkins B., Jones R.J., Woster P.M., Casero R.A. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin. Cancer Res. 2009, 15:7217-7228.
25. Johnson A.B., Denko N., Barton M.C. Hypoxia induces a novel signature of chromatin modifications and global repression of transcription. Mutat. Res. 2008, 640:174-179.
26. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
27. Jubb A.M., Buffa F.M., Harris A.L. Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J.Cell. Mol. Med. 2010, 14:18-29.
28. Kahl P., Gullotti L., Heukamp L.C., Wolf S., Friedrichs N., Vorreuther R., Solleder G., Bastian P.J., Ellinger J., Metzger E., et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006, 66:11341-11347.
29. Kolodner R.D., Hall N.R., Lipford J., Kane M.F., Rao M.R., Morrison P., Wirth L., Finan P.J., Burn J., Chapman P., et al. Human mismatch repair genes and their association with hereditary non-polyposis colon cancer. Cold Spring Harb. Symp. Quant. Biol. 1994, 59:331-338.
30. Lee M.G., Wynder C., Cooch N., Shiekhattar R. An essential rolefor CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 2005, 437:432-435.
31. Lu Y., Chu A., Turker M.S., Glazer P.M. Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter. Mol. Cell. Biol. 2011, 31:3339-3350.
32. McGarvey K.M., Fahrner J.A., Greene E., Martens J., Jenuwein T., Baylin S.B. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res. 2006, 66:3541-3549.
33. Meyers M., Wagner M.W., Hwang H.-S., Kinsella T.J., Boothman D.A. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res. 2001, 61:5193-5201.
34. Mihaylova V.T., Bindra R.S., Yuan J., Campisi D., Narayanan L., Jensen R., Giordano F., Johnson R.S., Rockwell S., Glazer P.M. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol. Cell. Biol. 2003, 23:3265-3273.
35. Mossman D., Scott R.J. Long term transcriptional reactivation ofepigenetically silenced genes in colorectal cancer cells requires DNA hypomethylation and histone acetylation. PLoS One 2011, 6:e23127.
36. Naqvi R.A., Hussain A., Deo S.S.V., Kukreti H., Chauhan M., Sarin R., Saxena A., Asim M., Shukla N.K., Husain S.A., et al. Hypermethylation analysis of mismatch repair genes (hmlh1 and hmsh2) in locally advanced breast cancers in Indian women. Hum. Pathol. 2008, 39:672-680.
37. Ooi S.K.T., Qiu C., Bernstein E., Li K., Jia D., Yang Z., Erdjument-Bromage H., Tempst P., Lin S.-P., Allis C.D., et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007, 448:714-717.
38. Palakurthy R.K., Wajapeyee N., Santra M.K., Gazin C., Lin L., Gobeil S., Green M.R. Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNMT3B expression. Mol. Cell 2009, 36:219-230.
39. Pérez-Carbonell L., Alenda C., Payá A., Castillejo A., Barberá V.M., Guillén C., Rojas E., Acame N., Gutiérrez-Aviñó F.J., Castells A., et al. Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome. J.Mol. Diagn. 2010, 12:498-504.
40. Reynolds T.Y., Rockwell S., Glazer P.M. Genetic instability induced by the tumor microenvironment. Cancer Res. 1996, 56:5754-5757.
41. Schenk T., Chen W.C., Göllner S., Howell L., Jin L., Hebestreit K., Klein H.-U., Popescu A.C., Burnett A., Mills K., et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med. 2012, 18:605-611.
42. Shi Y., Lan F., Matson C., Mulligan P., Whetstine J.R., Cole P.A., Casero R.A., Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119:941-953.
43. Shi Y.J., Matson C., Lan F., Iwase S., Baba T., Shi Y. Regulation of LSD1 histone demethylase activity by its associated factors. Mol. Cell 2005, 19:857-864.
44. Wang J., Scully K., Zhu X., Cai L., Zhang J., Prefontaine G.G., Krones A., Ohgi K.A., Zhu P., Garcia-Bassets I., et al. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 2007, 446:882-887.
45. Wang J., Hevi S., Kurash J.K., Lei H., Gay F., Bajko J., Su H., Sun W., Chang H., Xu G., et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat. Genet. 2009, 41:125-129.
46. Wang J., Lu F., Ren Q., Sun H., Xu Z., Lan R., Liu Y., Ward D., Quan J., Ye T., Zhang H. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 2011, 71:7238-7249.
47. Willmann D., Lim S., Wetzel S., Metzger E., Jandausch A., Wilk W., Jung M., Forne I., Imhof A., Janzer A., et al. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int. J. Cancer 2012, 131:2704-2709.
48. Xia X., Lemieux M.E., Li W., Carroll J.S., Brown M., Liu X.S., Kung A.L. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc. Natl. Acad. Sci. USA 2009, 106:4260-4265.
49. Xiong Z., Laird P.W. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997, 25:2532-2534.
50. Young S.D., Marshall R.S., Hill R.P. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc. Natl. Acad. Sci. USA 1988, 85:9533-9537.
51. Yuan J., Glazer P.M. Mutagenesis induced by the tumor microenvironment. Mutat. Res. 1998, 400:439-446.